

# Clinical decision-making in Rare Bone Diseases

A survey among EPOS and ERN-BOND members (September 2025)

<u>Thilini H. Gamage<sup>1</sup></u>, Lena Lande Wekre<sup>2</sup>, Silvia Coutinho<sup>2</sup>, Luca Sangiorgi<sup>3</sup>, Joachim Horn<sup>1,4</sup>

<sup>1</sup>Section of Children's Orthopaedics and Reconstructive Surgery, Division of Orthopaedics, Oslo University Hospital, , Norway <sup>2</sup>National Center for Rare Diagnoses, Sunnaas Unit, Norway <sup>3</sup>Department of Medical Genetics and Skeletal Rare Diseases, IRCCS Rizzoli Orthopaedic Institute, Bologna, Italy <sup>4</sup>Institute of Clinical Medicine, University of Oslo, Oslo, Norway

This presentation is generated within the European Reference Network on rare BONe Diseases which is partly co-funded by the European Union (Specific Grant Agreement no. 101157116). The contents of this presentation represents the views of the presenter(s) and is their sole responsibility; and do not necessarily reflect the opinion of the European Union.









## Rare bone diseases

- Rare disease prevalence (</=1/2000)</p>
- 771 Rare bone disorders
- Key challenges:
  - Clinical outcomes: highly variable
  - Delayed diagnosis
  - · Limited research on pathophysiology
  - Limited standardized frameworks
  - Extensive multidisciplinary needs



Image: www.jnj.com







#### Survey on Clinical Decision Making in Rare Bone Diseases



European Pediatric Orthopaedic Soceity (EPOS)



European Reference Network for Rare Bone Disorders (ERN BOND )

#### Objectives of the survey

- Describe current clinical practices in RBDs
- Identify unmet needs
- Outline minimum standards for patient assessment





#### **Structure**



- -Online survey (Google Forms)
- -35-items: (Multiple-choice, Likert scale, Open text)



#### **Participants**

Distributed to
EPOS & ERN-BOND members
(Sept 2025)



#### Requirements

Experience with RBD (clinic, laboratory, research, regulatory aspects)



#### **Ethical considerations**

- -Anonymous survey
- -Completion and submission implied consent for participation



#### **Data analysis**

- -Descriptive statistics
- -Thematic analysis




Dissemination

- -Report through EPOS/ERN-Bond channels
- -Peer-reviewed article





## ## 119 respondents from 35 countries completed the survey



The Netherlands
Spain
Germany
United States
Israel
France
Switzerland
Portugal
Poland
Denmark
Austria

© Australian Bureau of Statistics, GeoNames, Microsoft, Navinfo, Open Places, OpenStreetMap, Overture Maps Fundation, TomTom, Zenrin


Count of respondents 1 19








# Respondent Profile



#### Years of RBD experience







- Most manage common RBDs (osteogenesis imperfecta, fibrous dysplasia, achondroplasia, and multiple osteochondromas)
- Few have experience with ultra-rare conditions (FOP)

x-linkedhypophosphatemia hypophosphatasia achondroplasia fibrousdysplasia

osteogenesisimperfecta multipleosteochondromas

spondylothoracicdysostosis

pycnodisostosis

fibrodysplasiaossificansprogressiva

osteopetrosis


spondyloepiphysealdysplasia







## Similar practice in use anthropometric and growth parameters

- Height
- Weight
- Sitting height
- **Growth chart**
- **Body proportions**
- BMI







89%

## Similar practice in use posture and alignment in standing position and observation of gait

Similar practice in use posture and anginitent in standing position and observation of gait






Limb alignment



Observation of gait



Range of motion testing



Used: > 80%

> 90% 95%






## Variable use of Radiological parameters

Segmental radiographs
Long standing radiographs










# High resolution imaging (HR-pQCT)



31% 30%

100%

Used:




## High variability in use of advanced tools in routine RBD care

~50% used any type of gait-analysis tools/3D printing















## Most commonly used gait analysis tool-FGA

#### **Gait analysis tools**













- All acknowledged the importance of registry data
- But only 19% had access to national or international registry data to guide decisions.

# Importance of long-term studies in clinical decisions



#### Access to natural history data








## Interdisciplinary approach












## Interdisciplinary approach













#### Transition in care from paediatric to adult setting in RBD care

- Only 28% have a formal transition protocol
- >85% acknowledged the need for a formal protocol

#### Transition in care



#### Importance/need for guidelines










#### Transition in care from paediatric to adult setting in RBD care

- >50% named 3 or more challenges
  - Loss of follow-up or patient disengagement
  - Limited resources in adult services
  - Poor paediatric-adult care collaboration
  - Limited guidelines/protocols
  - Geographic barriers










# **Future Perspectives**

## Innovations shaping the future of RBDs

- Clinical and patient-centred care frameworks (64%)
- Technological innovations (36%)










# "Better integration of clinical, imaging, and functional data would improve clinical decision-making







- First pan-European survey within ERN-BOND and EPOS to systematically capture clinical decision-making in RBDs
- Similar practice in use of basic clinical parameters
- Considerable variability in use of more advanced techniques
- The findings underscore the importance and need of
  - standardized interdisciplinary care
  - national and international registry data
  - structured transition protocols



